Search

Your search keyword '"Pavone, Vincenzo"' showing total 1,423 results
Start Over Author "Pavone, Vincenzo"
1,423 results on '"Pavone, Vincenzo"'

2. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

3. Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial

Author

Clerico, Michele, Ferrero, Simone, Alessandria, Beatrice, Zaccaria, Gian Maria, Genuardi, Elisa, Ragaini, Simone, Tavarozzi, Rita, Cavallo, Federica, Hohaus, Stefan, Musuraca, Gerardo, Carella, Angelo Michele, Stelitano, Caterina, Tani, Monica, Gaidano, Gianluca, Olivieri, Jacopo, Usai, Sara Veronica, Galimberti, Sara, Re, Francesca, Mian, Michael, Castellino, Claudia, Pavone, Vincenzo, Evangelista, Andrea, Bruno, Benedetto, Cortelazzo, Sergio, Passera, Roberto, and Ladetto, Marco

Published
2024
Full Text
View/download PDF

5. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Author

Gini, Guido, Tani, Monica, Tucci, Alessandra, Marcheselli, Luigi, Cesaretti, Marina, Bellei, Monica, Pascarella, Anna, Ballerini, Filippo, Petrini, Mauro, Merli, Francesco, Olivieri, Attilio, Lanza, Francesco, Annibali, Ombretta, Zilioli, Vittorio Ruggero, Liberati, Anna Marina, Tisi, Maria Chiara, Arcari, Annalisa, Marino, Dario, Musuraca, Gerardo, Pavone, Vincenzo, Fabbri, Alberto, Pozzi, Samantha, Mannina, Donato, Plenteda, Caterina, Celli, Melania, and Luminari, Stefano

Published
2023
Full Text
View/download PDF

6. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

Author

Gaudio, Francesco, Loseto, Giacomo, Bozzoli, Valentina, Scalzulli, Potito Rosario, Mazzone, Anna Maria, Tonialini, Lorenzo, Fesce, Vincenza, Quintana, Giovanni, De Santis, Gaetano, Masciopinto, Pierluigi, Arcuti, Elena, Clemente, Felice, Scardino, Stefania, Tarantini, Giuseppe, Pastore, Domenico, Melillo, Lorella, Pavone, Vincenzo, Maggi, Alessandro, Carella, Angelo Michele, Di Renzo, Nicola, Guarini, Attilio, and Musto, Pellegrino

Published
2023
Full Text
View/download PDF

8. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Author

Mina, Roberto, Musto, Pellegrino, Rota-Scalabrini, Delia, Paris, Laura, Gamberi, Barbara, Palmas, Angelo, Aquino, Sara, de Fabritiis, Paolo, Giuliani, Nicola, De Rosa, Luca, Gozzetti, Alessandro, Cellini, Claudia, Bertamini, Luca, Capra, Andrea, Oddolo, Daniela, Vincelli, Iolanda Donatella, Ronconi, Sonia, Pavone, Vincenzo, Pescosta, Norbert, Cea, Michele, Fioritoni, Francesca, Ballanti, Stelvio, Grasso, Mariella, Zamagni, Elena, Belotti, Angelo, Boccadoro, Mario, and Gay, Francesca

Published
2023
Full Text
View/download PDF

9. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Author

Ferrero, Simone, Grimaldi, Daniele, Genuardi, Elisa, Drandi, Daniela, Zaccaria, Gian Maria, Alessandria, Beatrice, Ghislieri, Marco, Ferrante, Martina, Evangelista, Andrea, Mantoan, Barbara, De Luca, Gabriele, Stefani, Piero Maria, Benedetti, Fabio, Casaroli, Ivana, Zanni, Manuela, Castellino, Claudia, Pavone, Vincenzo, Petrini, Mario, Re, Francesca, Hohaus, Stefan, Musuraca, Gerardo, Cascavilla, Nicola, Ghiggi, Chiara, Liberati, Anna Marina, Cortelazzo, Sergio, and Ladetto, Marco

Published
2022
Full Text
View/download PDF

11. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

Author

Ricardi, Umberto, Levis, Mario, Evangelista, Andrea, Gioia, Daniela Maria, Sacchetti, Gian Mauro, Gotti, Manuel, Re, Alessandro, Buglione, Michela, Pavone, Vincenzo, Nardella, Antonio, Nassi, Luca, Zanni, Manuela, Franzone, Paola, Frezza, Giovanni Piero, Pulsoni, Alessandro, Grapulin, Lavinia, Santoro, Armando, Rigacci, Luigi, Simontacchi, Gabriele, Tani, Monica, Zaja, Francesco, Abruzzese, Elisabetta, Botto, Barbara, Zilioli, Vittorio Ruggero, Rota-Scalabrini, Delia, Freilone, Roberto, Ciccone, Giovannino, Filippi, Andrea Riccardo, and Zinzani, Pier Luigi

Published
2021
Full Text
View/download PDF

12. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

Author

Malagola, Michele, Polverelli, Nicola, Martino, Massimo, Patriarca, Francesca, Bruno, Benedetto, Giaccone, Luisa, Grillo, Giovanni, Bramanti, Stefania, Bernasconi, Paolo, De Gobbi, Marco, Natale, Annalisa, Terruzzi, Elisabetta, Olivieri, Attilio, Chiusolo, Patrizia, Carella, Angelo Michele, Casini, Marco, Maffini, Enrico, Nozzoli, Chiara, Mazza, Patrizio, Bassi, Simona, Onida, Francesco, Vacca, Adriana, Falcioni, Sadia, Luppi, Mario, Iori, Anna Paola, Pavone, Vincenzo, Skert, Cristina, Carluccio, Paola, Borghero, Carlo, Proia, Anna, Selleri, Carmine, Rubini, Vicky, Sacchi, Nicoletta, Oldani, Elena, Bonifazi, Francesca, Ciceri, Fabio, Russo, Domenico, Bernardi, Simona, Farina, Mirko, Fiore, Maria, Lupo Stanghellini, Maria Teresa, Fanin, Renato, Faraci, Danilo Giuseppe, Castagna, Luca, Colombo, Anna Amelia, Nicoli, Paolo, Santarone, Stella, Scortechini, Ilaria, Metafuni, Elisabetta, Merla, Emanuela, Cavattoni, Irene, Cutini, Ilaria, Mazzone, Annamaria, Saporiti, Giorgia, Canale, Filippo Antonio, Piras, Eugenia, Galieni, Piero, Debbia, Giulia, Rocca, Ursula La, Mele, Anna, Carobolante, Francesca, Elice, Francesca, and Fanelli, Fulvia

Published
2023
Full Text
View/download PDF

13. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, Luminari, Stefano, Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97

Published
2024

14. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, and Bari, Alessia

Subjects
CLINICAL trials, FOLLICULAR lymphoma, POSITRON emission tomography, OVERALL survival, PROGRESSION-free survival
Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1–3a FL/ stage II‐IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post‐induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1–3 was considered negative (CMR), whereas DS4‐5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients—52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3–5)—were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4–5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%–70%). The 5-yr PFS rate for PET neg (DS1–3) and PET pos (DS4–5) patients was 71% (95%CI: 67%–75%) and 36% (95%CI: 25%–46%), respectively, with HR 3.49 (95%CI: 2.57–4.72). Five-year PFS was worse as DS increased, with 74% (70%–78%), 58% (48%–67%; HR 1.71; p = 0.001)] and 36% (25%–46%; HR 3.88; p < 0.001) in DS1–2, DS3 and DS4–5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%–96%), with 96% (95%CI: 94–97) and 82% (95%CI: 72%–89%) in EOI PET negative (DS1–3) and positive (DS4–5), respectively (HR 4.48; p < 0.001). When DS was associated with FLIPI-2, patients with DS3 or DS1–2 with high FLIPI-2 (3–5) experienced worse OS than patients with DS1–2 and low FLIPI-2 (1–2) (p = 0.003). Conclusion: This study shows that DS is a reliable prognostic tool to evaluate EOI PET in follicular lymphoma patients, with prognostic value maintained both in the standard and experimental arms, making metabolic imaging a robust tool to assess response in FL. Moreover, although preliminary, this study provides further information on DS3 patients, who are considered as CMR but show a less favourable PFS than DS1–2 patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Cavo, Michele, Fanin, Renato, Foa', Roberto, Rambaldi, Alessandro, Di Raimondo, Francesco, Rossi, Giuseppe, Boccadoro, Mario, Leoni, Pietro, Corradini, Paolo, Torelli, Giuseppe, Fioritoni, Giuseppe, Cortelazzo, Sergio, Lambertenghi Deliliers, Giorgio, La Nasa, Giorgio, Zaccaria, Alfonso, De Fabritiis, Paolo, Cascavilla, Nicola, Bosi, Alberto, Semenzato, Gianpietro, Gugliotta, Luigi, Gherlinzoni, Filippo, Angelucci, Emanuele, Martelli, Massimo Fabrizio, Petti, Maria Concetta, Leone, Giuseppe, Carella, Angelo Michele, Ciceri, Fabio, Santoro, Armando, Ferrara, Felicetto, Nobile, Francesco, D'Arco, Alfonso Maria, Levis, Alessandro, Guardigni, Luciano, Gallamini, Andrea, Musto, Pellegrino, Fattori, Pier Paolo, Galieni, Piero, Morandi, Sergio, Amadori, Dino, Gobbi, Marco, Rotoli, Bruno, Mirto, Salvatore, Lazzaro, Antonio, Paladini, Giorgio, Mozzana, Ruggero, Pinotti, Graziella, Rodeghiero, Francesco, Cantore, Nicola, Pavone, Vincenzo, Pogliani, Enrico Maria, Liberati, Anna Marina, Majolino, Ignazio, Amadori, Sergio, Lauria, Francesco, Aglietta, Massimo, Quarta, Giovanni, Storti, Sergio, Morabito, Fortunato, Capalbo, Silvana Franca, Gianni, Alessandro Massimo, Mettivier, Vincenzo, Rizzoli, Vittorio, Bernasconi, Carlo, Visani, Giuseppe, Pizzuti, Michele, La Verde, Giacinto, Avvisati, Giuseppe, Longinotti, Maurizio, Gallo, Eugenio, Dammacco, Franco, Russo, Domenico, Bacigalupo, Andrea, Musolino, Caterina, Tacchetti, Paola, Pantani, Lucia, Patriarca, Francesca, Petrucci, Maria Teresa, Zamagni, Elena, Dozza, Luca, Galli, Monica, Crippa, Claudia, Barbato, Simona, Tosi, Patrizia, Narni, Franco, Montefusco, Vittorio, Testoni, Nicoletta, Spadano, Antonio, Terragna, Carolina, Pescosta, Norbert, Marzocchi, Giulia, Cellini, Claudia, Ronconi, Sonia, Catalano, Lucio, De Sabbata, Giovanni, Cangialosi, Clotilde, Ciambelli, Fabrizio, and Elice, Francesca

Published
2020
Full Text
View/download PDF

17. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, primary, Bertuglia, Giuseppe, additional, Rota-Scalabrini, Delia, additional, Belotti, Angelo, additional, Morè, Sonia, additional, Corradini, Paolo, additional, Oliva, Stefania, additional, Ledda, Antonio, additional, Grasso, Mariella, additional, Pavone, Vincenzo, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Ballanti, Stelvio, additional, Velluti, Cristina, additional, Cellini, Claudia, additional, Gozzetti, Alessandro, additional, Palmas, Angelo D., additional, Gamberi, Barbara, additional, Mancuso, Katia, additional, Paris, Laura, additional, Zambello, Renato, additional, Petrucci, Maria Teresa, additional, Bruno, Benedetto, additional, Musto, Pellegrino, additional, and Gay, Francesca, additional

Published
2024
Full Text
View/download PDF

18. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

Author

Mele, Anna, Prete, Eleonora, De Risi, Clara, Citiso, Stefania, Greco, Giuseppina, Falcone, Antonietta Pia, Sanpaolo, Grazia, Mele, Giuseppe, Giannotta, Angela, Vergine, Carolina, Reddiconto, Giovanni, Palazzo, Giulia, Sabatelli, Sabrina, Germano, Candida, Miccolis, Rosanna, Curci, Paola, Palumbo, Gaetano, Offidani, Massimo, Rizzi, Rita, Cascavilla, Nicola, Pastore, Domenico, Di Renzo, Nicola, Mazza, Patrizio, Tarantini, Giuseppe, Guarini, Attilio, Capalbo, Silvana, Specchia, Giorgina, Greco, Antonino, De Francesco, Rosa, Sibilla, Silvia, Tonialini, Lorenzo, Morciano, Maria Rosaria, and Pavone, Vincenzo

Published
2021
Full Text
View/download PDF

20. Conclusion

Author

Pavone, Vincenzo, Goven, Joanna, Pavone, Vincenzo, editor, and Goven, Joanna, editor

Published
2017
Full Text
View/download PDF

22. Introduction

Author

Pavone, Vincenzo, Goven, Joanna, Pavone, Vincenzo, editor, and Goven, Joanna, editor

Published
2017
Full Text
View/download PDF

25. El papel de las ciencias sociales en el asesoramiento científico

Author

Pavone, Vincenzo [0000-0002-2326-0118], Brandts, Jordi [0000-0001-9082-9258], Serrano del Rosal, Rafael [0000-0002-9488-8295], Pavone, Vincenzo, Molas, Jordi, Brandts, Jordi, Serrano del Rosal, Rafael, Pavone, Vincenzo [0000-0002-2326-0118], Brandts, Jordi [0000-0001-9082-9258], Serrano del Rosal, Rafael [0000-0002-9488-8295], Pavone, Vincenzo, Molas, Jordi, Brandts, Jordi, and Serrano del Rosal, Rafael

Published
2023

26. Eggonomics: Vitrification and bioeconomies of egg donation in the United States and Spain

Author

National Science Foundation (US), Pavone, Vincenzo [0000-0002-2326-0118], Tober, Diane, Pavone, Vincenzo, Lafuente-Funes, Sara, Konvalinka, Nancy, National Science Foundation (US), Pavone, Vincenzo [0000-0002-2326-0118], Tober, Diane, Pavone, Vincenzo, Lafuente-Funes, Sara, and Konvalinka, Nancy

Abstract

Regulations governing assisted reproduction control the degree to which gamete donation is legal and how people providing genetic material are selected and compensated. The United States and Spain are both global leaders in fertility treatment with donor oocytes. Yet both countries take different approaches to how egg donation is regulated. The US model reveals a hierarchically organized form of gendered eugenics. In Spain, the eugenic aspects of donor selection are more subtle. Drawing upon fieldwork in the United States and Spain, this article examines (1) how compensated egg donation operates under two regulatory settings, (2) the implications for egg donors as providers of bioproducts, and (3) how advances in oocyte vitrification enhances the commodity quality of human eggs. By comparing these two reproductive bioeconomies we gain insight into how different cultural, medical, and ethical frameworks intersect with egg donor embodied experiences.

Published
2023

27. Artificial Diiron Enzymes with a De Novo Designed Four‐Helix Bundle Structure

Author

Chino, Marco, Maglio, Ornella, Nastri, Flavia, Pavone, Vincenzo, DeGrado, William F, and Lombardi, Angela

Subjects
Inorganic Chemistry, Chemical Sciences, Underpinning research, 1.1 Normal biological development and functioning, Generic health relevance, Enzyme mimics, Metalloenzymes, Protein design, Helical structures, Iron, DF models, Other Chemical Sciences, Inorganic & Nuclear Chemistry, Inorganic chemistry
Abstract

A single polypeptide chain may provide an astronomical number of conformers. Nature selected only a trivial number of them through evolution, composing an alphabet of scaffolds, that can afford the complete set of chemical reactions needed to support life. These structural templates are so stable that they allow several mutations without disruption of the global folding, even having the ability to bind several exogenous cofactors. With this perspective, metal cofactors play a crucial role in the regulation and catalysis of several processes. Nature is able to modulate the chemistry of metals, adopting only a few ligands and slightly different geometries. Several scaffolds and metal-binding motifs are representing the focus of intense interest in the literature. This review discusses the widespread four-helix bundle fold, adopted as a scaffold for metal binding sites in the context of de novo protein design to obtain basic biochemical components for biosensing or catalysis. In particular, we describe the rational refinement of structure/function in diiron-oxo protein models from the due ferri (DF) family. The DF proteins were developed by us through an iterative process of design and rigorous characterization, which has allowed a shift from structural to functional models. The examples reported herein demonstrate the importance of the synergic application of de novo design methods as well as spectroscopic and structural characterization to optimize the catalytic performance of artificial enzymes.

Published
2015

29. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Gagelmann, Nico, Eikema, Diderik-Jan, Koster, Linda, Caillot, Denis, Pioltelli, Pietro, Lleonart, Juan Bargay, Reményi, Péter, Blaise, Didier, Schaap, Nicolaas, Trneny, Marek, Passweg, Jakob, Porras, Rocio Parody, Cahn, Jean Yves, Musso, Maurizio, Poiré, Xavier, Fenk, Roland, Itälä-Remes, Maija, Pavone, Vincenzo, Fouillard, Loic, Maertens, Johan, Bron, Dominique, Pouli, Anastasia, Schroyens, Wilfried, Schönland, Stefan, Garderet, Laurent, Yakoub-Agha, Ibrahim, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

32. Crystal structure of an amphiphilic foldamer reveals a 48-mer assembly comprising a hollow truncated octahedron.

Author

Pavone, Vincenzo, Zhang, Shao-Qing, Merlino, Antonello, Lombardi, Angela, Degrado, William, and Wu, Yibing

Subjects
Hydrogen Bonding, Polymers, Protein Folding, Protein Structure, Secondary
Abstract

Foldamers provide an attractive medium to test the mechanisms by which biological macromolecules fold into complex three-dimensional structures, and ultimately to design novel protein-like architectures with properties unprecedented in nature. Here, we describe a large cage-like structure formed from an amphiphilic arylamide foldamer crystallized from aqueous solution. Forty-eight copies of the foldamer assemble into a 5-nm cage-like structure, an omnitruncated octahedron filled with well-ordered ice-like water molecules. The assembly is stabilized by a mix of arylamide stacking interaction, hydrogen bonding and hydrophobic forces. The omnitruncated octahedra tessellate to form a cubic crystal. These findings may provide an important step towards the design of nanostructured particles resembling spherical viruses.

Published
2014

36. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms

Author

Malagola, Michele, Polverelli, Nicola, Rubini, Vicky, Martino, Massimo, Patriarca, Francesca, Bruno, Benedetto, Giaccone, Luisa, Grillo, Giovanni, Bramanti, Stefania, Bernasconi, Paolo, De Gobbi, Marco, Natale, Annalisa, Terruzzi, Elisabetta, Olivieri, Attilio, Chiusolo, Patrizia, Carella, Angelo Michele, Casini, Marco, Nozzoli, Chiara, Mazza, Patrizio, Bassi, Simona, Onida, Francesco, Vacca, Adriana, Falcioni, Sadia, Luppi, Mario, Iori, Anna Paola, Pavone, Vincenzo, Skert, Cristina, Carluccio, Paola, Borghero, Carlo, Proia, Anna, Selleri, Carmine, Sacchi, Nicoletta, Mammoliti, Sonia, Oldani, Elena, Ciceri, Fabio, Russo, Domenico, and Bonifazi, Francesca

Published
2022
Full Text
View/download PDF

42. Dye decolorization by a miniaturized peroxidase Fe-MimochromeVI*a

Author

Chino, Marco, Russo, Roberto, La Gatta, Salvatore, Leone, Linda, De Fenza, Maria, Lombardi, Angela, Pavone, Vincenzo, and Maglio, Ornella

Abstract

Raw and processed data for the study "Dye decolorization by a miniaturized peroxidase Fe-MimochromeVI*a" published on International Journal of Molecular Sciences (MDPI, Basel, Switzerland), and freely available at the following link: https://doi.org/10.3390/ Abstract: Oxidases and peroxidases have found application in the field of chlorine-free organic dye degradation in the paper, toothpaste, and detergent industries. Nevertheless, their widespread use is somehow hindered because of their cost, availability, and batch-to-batch reproducibility. Here, we report the catalytic proficiency of a miniaturized synthetic peroxidase, Fe-Mimochrome VI*a, in the decolorization of four organic dyes, as representatives of either the heterocyclic or triarylmethane class of dyes. Fe-Mimochrome VI*a performed over 130 turnovers in less than five minutes in an aqueous buffer at a neutral pH under mild conditions., This research was funded by the Italian Ministry of University and Research, PRIN 2020, Project SEA-WAVE 2020BKK3W9 (CUP E69J22001140005).

Published
2023
Full Text
View/download PDF

44. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)

Author

Pavone, Vincenzo, Mele, Anna, Carlino, Daniela, Specchia, Giorgina, Gaudio, Francesco, Perrone, Tommasina, Mazza, Patrizio, Palazzo, Giulia, Guarini, Attilio, Loseto, Giacomo, Eleonora, Prete, Cascavilla, Nicola, Scalzulli, Potito, Melpignano, Angela, Quintana, Giovanni, Di Renzo, Nicola, Tarantini, Giuseppe, and Capalbo, Silvana

Published
2018
Full Text
View/download PDF

45. Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)

Author

Ravaioli, Federico, primary, Colecchia, Antonio, additional, Barbato, Francesco, additional, Peccatori, Jacopo, additional, Grassi, Anna, additional, Sarina, Barbara, additional, Pompili, Maurizio, additional, Sica, Simona, additional, Locatelli, Franco, additional, Cesaro, Simone, additional, Nozzoli, Chiara, additional, Iori, Anna Paola, additional, Prezioso, Lucia, additional, Santarone, Stella, additional, Fagioli, Franca, additional, Olivieri, Attilio, additional, Vanni, Ester, additional, Specchia, Giorgina, additional, Benedetti, Edoardo, additional, Zallio, Francesco, additional, Pane, Fabrizio, additional, Carobolante, Francesca, additional, Menconi, Maria Cristina, additional, Benedetti, Fabio, additional, Patriarca, Francesca, additional, Malagola, Michele, additional, Varaldo, Riccardo, additional, Onida, Francesco, additional, Pavone, Vincenzo, additional, Vestito, Amanda, additional, Colecchia, Luigi, additional, Dajti, Elton, additional, Alemanni, Luigina Vanessa, additional, Marasco, Giovanni, additional, Ciceri, Fabio, additional, Prete, Arcangelo, additional, Pession, Andrea, additional, Festi, Davide, additional, and Bonifazi, Francesca, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results